Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.

The U-A10 cell line, a doxorubicin-selected variant of human U-937 myeloid leukemia cells, exhibits a redistribution of anthracyclines into a expanded vesicular compartment. The acidic nature of this compartment was confirmed by vital staining with a pH sensitive dye, LysoSensor yellow/blue DND-160. Identification of the vesicular compartment was performed by immunofluorescence analysis. Staining for the LAMP-1 and LAMP-2 antigens showed that the vesicles are enlarged lysosomes that are eccentrically placed near the nucleus of U-A10 cells. By contrast, the expression of the multidrug resistance-associated protein and the P-glycoprotein was observed predominately on the plasma membrane of the drug-resistant cells. The accumulation of daunorubicin into cellular compartments was quantified using radiolabeled drug. Exposing cells to 3[H]-daunorubicin and then isolating intact nuclei showed that nuclei from U-A10 cells accumulated twofold to threefold less anthracycline than nuclei from U-937 cells. However, when nuclei were isolated first and then exposed to 3[H]-daunorubicin, little difference in net nuclear drug accumulation was detected. Cytoplasts prepared from U-A10 and U-937 cells were exposed to 3[H]-daunorubicin to measure cytoplasmic drug accumulation. At external daunorubicin concentrations of 100 ng/mL or higher, cytoplasts from U-A10 cells accumulated significantly more daunorubicin than cytoplasts from U-937 cells. Moreover, studies with the lysosomotropic agent chloroquine showed that U-A10 cells accumulated twofold more chloroquine and showed twofold enhanced sensitivity to this agent as compared with parental U-937 cells. Fluorescence microscopy showed that chloroquine affects vesicular anthracycline sequestration in U-A10 cells with an associated increase in daunorubicin nuclear fluorescence. Although chloroquine did not alter anthracycline cytotoxicity in parental cells, it restored daunorubicin and doxorubicin sensitivity to U-A10 cells. Taken together, these studies demonstrate that U-A10 cells exhibit a redistribution of the lysosomal compartment. The trapping of drug into an expanded acidic vesicular compartment results in decreased nuclear drug accumulation and decreased cytotoxicity. Lysosomotropic agents, such as chloroquine, warrant further study as modulators of this acquired drug-resistance phenotype.

[1]  V. Ling,et al.  P‐glycoprotein: multidrug‐resistance and a superfamily of membrane‐associated transport proteins , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  A. Safa,et al.  Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. , 1994, Oncology research.

[3]  W. T. Beck,et al.  Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. , 1988, Biochemical and biophysical research communications.

[4]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[5]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[6]  M. Kobayashi,et al.  Lysosomotropic agents reverse multiple drug resistance in human cancer cells. , 1986, Cancer letters.

[7]  P. Tulkens,et al.  Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts. , 1978, European journal of cancer.

[8]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[9]  W. T. Beck,et al.  Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug resistant human leukemic cells. , 1986, Biochemical pharmacology.

[10]  S. Cole,et al.  Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. , 1996, Biochemical pharmacology.

[11]  J. Thomas August,et al.  Purification and characterization of human lysosomal membrane glycoproteins. , 1989, Archives of biochemistry and biophysics.

[12]  V. Volloch,et al.  Synthesis of globin RNA in enucleated differentiating murine erythroleukemia cells , 1987, The Journal of cell biology.

[13]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Sheppard,et al.  RECENT DEVELOPMENTS IN THE , 1966 .

[15]  G. M. Wilson,et al.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.

[16]  M. Fukuda,et al.  Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular trafficking. , 1991, The Journal of biological chemistry.

[17]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[18]  D. Marquardt,et al.  Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. , 1992, Cancer research.

[19]  P. Gros,et al.  Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. , 1989, Cancer research.

[20]  D. Kufe,et al.  Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. , 1994, Blood.

[21]  P. Workman,et al.  Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. , 1993, British Journal of Cancer.

[22]  I. Pastan,et al.  A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Hoffmann,et al.  Doxorubicin (Adriamycin) transport in Ehrlich ascites tumour cells: comparison with transport in human red blood cells. , 1983, Scandinavian journal of clinical and laboratory investigation.

[24]  M. Wigler,et al.  A preparative method for obtaining enucleated mammalian cells. , 1975, Biochemical and biophysical research communications.

[25]  E. Titus Recent developments in the understanding of the pharmacokinetics and mechanism of action of chloroquine. , 1989, Therapeutic drug monitoring.

[26]  H. Clevers,et al.  The drug resistance-related protein LRP is the human major vault protein , 1995, Nature Medicine.

[27]  J. Gervasoni,et al.  Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. , 1991, Cancer research.

[28]  J. Baak,et al.  Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. , 1991, British Journal of Cancer.

[29]  Vanholde Ke,et al.  Isolation and characterization of chromatin subunits. , 1978, Methods in cell biology.

[30]  I. Pastan,et al.  Fluorescent cellular indicators are extruded by the multidrug resistance protein. , 1993, The Journal of biological chemistry.

[31]  S. Ohkuma,et al.  Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages , 1981, The Journal of cell biology.

[32]  M. Dalmark,et al.  A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells , 1981, The Journal of general physiology.

[33]  D. Hipfner,et al.  Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. , 1994, Cancer research.

[34]  S. Aaronson,et al.  Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. , 1995, Cancer research.

[35]  I. Pastan,et al.  Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. , 1986, Cancer research.

[36]  V. Ling,et al.  Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies , 1985, Nature.

[37]  J. Belli,et al.  Sequestration of doxorubicin in vesicles in a multidrug-resistant cell line (LZ-100). , 1994, Biochemical pharmacology.

[38]  R. Prokesch,et al.  Antibiotic entry into human polymorphonuclear leukocytes , 1982, Antimicrobial Agents and Chemotherapy.

[39]  F. Baas,et al.  The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. , 1994, Proceedings of the National Academy of Sciences of the United States of America.